To the best of our knowledge, our study for the first time illustrated that stigmasterol is the main active component of AhBl and it could target PPARγ to exert effects on inhibiting tumorigenesis and tumor growth of lung adenocarcinoma, providing an experimental basis for stigmasterol as a therapeutic for cancer treatment. This evidence concerns the gene PPARG and lung adenocarcinoma.